| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07276997 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | PHASE2 | RECRUITING | 195 | — | — | Dec 18, 2025 | Sep 1, 2027 | May 13, 2026 | 33 | United States |
Montgomery-Åsberg Depression Rating Scale (MADRS) The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are to be rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
| Arm | Type | Description |
|---|---|---|
| Icalcaprant Dose A | EXPERIMENTAL | Participants will receive oral Icalcaprant dose A once daily for 6 weeks and attend a follow up visit 30 days following end of treatment. |
| Icalcaprant Dose B | EXPERIMENTAL | Participants will receive oral Icalcaprant dose B once daily for 6 weeks and attend a follow up visit 30 days following end of treatment. |
| Placebo for Icalcaprant | PLACEBO_COMPARATOR | Participants will receive oral placebo once daily for 6 weeks and attend a follow up visit 30 days following end of treatment. |
| Name | Type | Description |
|---|---|---|
| Icalcaprant | DRUG | Oral Capsules |
| Placebo for Icalcaprant | DRUG | Oral Capsules |
Inclusion Criteria: * Participants with a diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision (DSM-5-TR) without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI) 7....